|
EXHIBIT
10.1
Portions of this Exhibit were omitted
and filed separately with the Secretary of the Commission pursuant
to an application for confidential treatment filed with the
Commission pursuant to Rule 24b-2 under the Securities Exchange Act
of 1934. Such omissions are designated as ***.
AMENDMENT NO. 1
TO
LICENSE
AGREEMENT
DATED AS OF APRIL 13,
2002
BY AND
BETWEEN
UNIGENE LABORATORIES,
INC.
AND
SMITHKLINE BEECHAM
CORPORATION
This Amendment No. 1
(“Amendment”) dated as of January 16, 2003
(“Amendment Date”), to the License Agreement (referred
to hereinafter as the “Agreement”) entered into as of
the 13th of April, 2002, by and between Unigene Laboratories, Inc.
(“Unigene”), a Delaware corporation, and SmithKline
Beecham Corporation, a GlaxoSmithKline company (“GSK”),
a Pennsylvania corporation.
RECITALS:
WHEREAS, GSK and Unigene
entered into the Agreement to provide for the license grant by
Unigene to GSK of certain Licensed Products (as defined in the
Agreement) to discover, develop, make, have made, market, sell and
import certain Licensed Products (as defined in the Agreement)
throughout the world under the Unigene Patent Rights (as defined in
the Agreement) and Unigene Know-How (as defined in the Agreement);
and
WHEREAS, pursuant to
Section 11.10 of the Agreement, the parties to the Agreement
may, by written instruments specifically referring to and executed
in the same manner as the Agreement, amend the Agreement;
and
WHEREAS, the parties hereto
desire to amend the Agreement as provided herein.
NOW THEREFORE, for and in
consideration of the premises and the mutual promises and benefits
contained herein, GSK and Unigene hereby agree as
follows:
1. Section 3.2(a) of the
Agreement is
| 
